Distillate Capital Partners LLC Increases Position in Elevance Health, Inc. $ELV

Distillate Capital Partners LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV) by 31.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 76,502 shares of the company’s stock after acquiring an additional 18,508 shares during the quarter. Elevance Health makes up 1.3% of Distillate Capital Partners LLC’s portfolio, making the stock its 19th biggest position. Distillate Capital Partners LLC’s holdings in Elevance Health were worth $24,730,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. raised its position in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares in the last quarter. Activest Wealth Management grew its position in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Rossby Financial LCC grew its position in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in shares of Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares during the last quarter. Finally, Motco raised its holdings in Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 77 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 1.3%

ELV stock opened at $291.69 on Monday. The firm has a market cap of $64.38 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.61 and a beta of 0.51. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The firm has a fifty day moving average price of $338.25 and a two-hundred day moving average price of $334.45. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the firm posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is 27.39%.

Analyst Upgrades and Downgrades

A number of research firms have commented on ELV. Weiss Ratings downgraded shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a research note on Tuesday, February 3rd. Leerink Partners increased their price target on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Wells Fargo & Company decreased their price target on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Finally, UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.